These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 7736689)

  • 21. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.
    Craig WA
    Infect Dis Clin North Am; 2003 Sep; 17(3):479-501. PubMed ID: 14711073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of fluoroquinolones.
    Lode H; Borner K; Koeppe P
    Clin Infect Dis; 1998 Jul; 27(1):33-9. PubMed ID: 9675446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic pharmacokinetic and pharmacodynamic parameters in pediatric clinical practice.
    Cohen R; Grimprel E
    Arch Pediatr; 2017 Dec; 24(12S):S6-S8. PubMed ID: 29290237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.
    Winterboer TM; Lecci KA; Olsen KM
    J Pharm Pract; 2010 Feb; 23(1):6-18. PubMed ID: 21507788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.
    Ernst EJ; Klepser ME; Petzold CR; Doern GV
    Pharmacotherapy; 2002 Apr; 22(4):463-70. PubMed ID: 11939681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.
    Dudley MN
    Am J Med; 1991 Dec; 91(6A):45S-50S. PubMed ID: 1767806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf.
    Shojaee Aliabadi F; Lees P
    Res Vet Sci; 2003 Jun; 74(3):247-59. PubMed ID: 12726744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology].
    Isla A; Canut A; Rodríguez-Gascón A; Labora A; Ardanza-Trevijano B; Solinís MA; Pedraz JL
    Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):116-21. PubMed ID: 15757581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
    Touw DJ; Vinks AA; Mouton JW; Horrevorts AM
    Clin Pharmacokinet; 1998 Dec; 35(6):437-59. PubMed ID: 9884816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.
    Rubino CM; Bradley JS
    Paediatr Drugs; 2007; 9(6):361-9. PubMed ID: 18052406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of antimicrobial therapy in surgery.
    DiPiro JT; Edmiston CE; Bohnen JM
    Am J Surg; 1996 Jun; 171(6):615-22. PubMed ID: 8678212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.